The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

S100A8/A9 as a biomarker for synovial inflammation and joint damage in patients with rheumatoid arthritis

  • Kang, Kwi Young (Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea College of Medicine) ;
  • Woo, Jung-Won (Department of Convergent Research Consortium for Immunologic Disease, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine) ;
  • Park, Sung-Hwan (Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea College of Medicine)
  • Received : 2013.12.10
  • Accepted : 2013.12.14
  • Published : 2014.01.01
⟨ Previous Next ⟩

Abstract

S100A8 and S100A9 are major leukocyte proteins, known as damage-associated molecular patterns, found at high concentrations in the synovial fluid of patients with rheumatoid arthritis (RA). A heterodimeric complex of S100A8/A9 is secreted by activated leukocytes and binds to Toll-like receptor 4, which mediates downstream signaling and promotes inflammation and autoimmunity. Serum and synovial fluid levels of S100A8/A9 are markedly higher in patients with RA than in patients with osteoarthritis or miscellaneous inflammatory arthritis. Serum levels of S100A8/A9 are significantly correlated with clinical and laboratory markers of inf lammation, such as C-reactive protein, erythrocyte sedimentation rate, rheumatoid factor, and the Disease Activity Score for 28 joints. Significant correlations have also been found between S100A8/A9 and radiographic and clinical assessments of joint damage, such as hand radiographs and the Rheumatoid Arthritis Articular Damage score. In addition, among known inflammatory markers, S100A8/A9 has the strongest correlation with total sum scores of ultrasonography assessment. Furthermore, baseline levels of S100A8/A9 are independently associated with progression of joint destruction in longitudinal studies and are responsive to change during conventional and biologic treatments. These findings suggest S100A8/A9 to be a valuable diagnostic and prognostic biomarker for RA.

Keywords

References

  1. Andersson AK, Li C, Brennan FM. Recent developments in the immunobiology of rheumatoid arthritis. Arthritis Res Ther 2008;10:204. https://doi.org/10.1186/ar2370
  2. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T. Synovial fibroblasts: key players in rheumatoid arthritis. Rheumatology (Oxford) 2006;45:669-675. https://doi.org/10.1093/rheumatology/kel065
  3. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-442. https://doi.org/10.1038/nri2094
  4. Park SH. New diagnostic method of rheumatoid arthritis. Korean J Med 2009;76:7-11.
  5. Park SH. Guideline for treatment or rheumatoid arthritis. Korean J Med 2010;79:s455-s458.
  6. Leclerc E, Fritz G, Vetter SW, Heizmann CW. Binding of S100 proteins to RAGE: an update. Biochim Biophys Acta 2009;1793:993-1007. https://doi.org/10.1016/j.bbamcr.2008.11.016
  7. Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007;13:1042-1049. https://doi.org/10.1038/nm1638
  8. Berntzen HB, Munthe E, Fagerhol MK. A longitudinal study of the leukocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol 1989;16:1416-1420.
  9. Brun JG, Haga HJ, Boe E, et al. Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J Rheumatol 1992;19:859-862.
  10. Brun JG, Jonsson R, Haga HJ. Measurement of plasma calprotectin as an indicator of arthritis and disease activity in patients with inflammatory rheumatic diseases. J Rheumatol 1994;21:733-738.
  11. Bakker MF, Cavet G, Jacobs JW, et al. Performance of a multi-biomarker score measuring rheumatoid arthritis disease activity in the CAMERA tight control study. Ann Rheum Dis 2012;71:1692-1697. https://doi.org/10.1136/annrheumdis-2011-200963
  12. Dale I, Brandtzaeg P, Fagerhol MK, Scott H. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leukocytes: immunof luorescence and immunoperoxidase staining features in comparison with lysozyme and lactoferrin. Am J Clin Pathol 1985;84:24-34. https://doi.org/10.1093/ajcp/84.1.24
  13. Foell D, Roth J. Proinf lammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004;50:3762-3771. https://doi.org/10.1002/art.20631
  14. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 1980;16 Suppl:273-282.
  15. Edgeworth J, Gorman M, Bennett R, Freemont P, Hogg N. Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem 1991;266:7706-7713.
  16. Wolf R, Howard OM, Dong HF, et al. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol 2008;181:1499-1506. https://doi.org/10.4049/jimmunol.181.2.1499
  17. Ehrchen JM, Sunderkotter C, Foell D, Vogl T, Roth J. The endogenous Toll-like receptor 4 agonist S100A8/ S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol 2009;86:557-566. https://doi.org/10.1189/jlb.1008647
  18. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007;81:1-5. https://doi.org/10.1189/jlb.0306164
  19. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. J Leukoc Biol 2007;81:28-37. https://doi.org/10.1189/jlb.0306170
  20. Foell D, Wittkowski H, Roth J. Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007;3:382-390.
  21. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem 1997;272:9496-9502. https://doi.org/10.1074/jbc.272.14.9496
  22. Ghavami S, Rashedi I, Dattilo BM, et al. S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 2008;83:1484-1492. https://doi.org/10.1189/jlb.0607397
  23. Tamaki Y, Takakubo Y, Hirayama T, et al. Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis. J Rheumatol 2011;38:810-820. https://doi.org/10.3899/jrheum.100732
  24. Malemud CJ. Myeloid-related protein activity in rheumatoid arthritis. Int J Inflam 2011;2011:580295.
  25. Goh FG, Midwood KS. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology (Oxford) 2012;51:7-23. https://doi.org/10.1093/rheumatology/ker257
  26. Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000;43:628-637. https://doi.org/10.1002/1529-0131(200003)43:3<628::AID-ANR20>3.0.CO;2-X
  27. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol Pathol 1997;50:113-123. https://doi.org/10.1136/mp.50.3.113
  28. Loser K, Vogl T, Voskort M, et al. The Toll-like receptor 4 ligands Mrp8 and Mrp14 are crucial in the development of autoreactive CD8+ T cells. Nat Med 2010;16:713-717. https://doi.org/10.1038/nm.2150
  29. Liao H, Wu J, Kuhn E, et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum 2004;50:3792-3803. https://doi.org/10.1002/art.20720
  30. Sunahori K, Yamamura M, Yamana J, et al. The S100A8/A9 heterodimer amplifies proinf lammatory cytokine production by macrophages via activation of nuclear factor kappa B and p38 mitogen-activated protein kinase in rheumatoid arthritis. Arthritis Res Ther 2006;8:R69. https://doi.org/10.1186/ar1939
  31. Hammer HB, Haavardsholm EA, Kvien TK. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis. Scand J Rheumatol 2008;37:179-182. https://doi.org/10.1080/03009740701874451
  32. Pap T, Muller-Ladner U, Gay RE, Gay S. Fibroblast biology: role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000;2:361-367. https://doi.org/10.1186/ar113
  33. Baillet A, Trocme C, Berthier S, et al. Synovial fluid proteomic fingerprint: S100A8, S100A9 and S100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases. Rheumatology (Oxford) 2010;49:671-682. https://doi.org/10.1093/rheumatology/kep452
  34. Youssef P, Roth J, Frosch M, et al. Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol 1999;26:2523-2528.
  35. Lee DG, Woo JW, Kwok SK, Cho ML, Park SH. MRP8 promotes Th17 differentiation via upregulation of IL-6 production by fibroblast-like synoviocytes in rheumatoid arthritis. Exp Mol Med 2013;45:e20. https://doi.org/10.1038/emm.2013.39
  36. Dale I, Fagerhol MK, Naesgaard I. Purification and partial characterization of a highly immunogenic human leukocyte protein, the L1 antigen. Eur J Biochem 1983;134:1-6. https://doi.org/10.1111/j.1432-1033.1983.tb07522.x
  37. Hammer HB, Odegard S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inf lammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007;66:1093-1097. https://doi.org/10.1136/ard.2006.064741
  38. Andres Cerezo L, Mann H, Pecha O, et al. Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. Arthritis Res Ther 2011;13:R122. https://doi.org/10.1186/ar3426
  39. Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther 2011;13:R178. https://doi.org/10.1186/ar3503
  40. Odegard S, Landewe R, van der Heijde D, Kvien TK, Mowinckel P, Uhlig T. Association of early radiographic damage with impaired physical function in rheumatoid arthritis: a ten-year, longitudinal observational study in 238 patients. Arthritis Rheum 2006;54:68-75. https://doi.org/10.1002/art.21548
  41. Jansen LM, van der Horst-Bruinsma IE, van Schaardenburg D, Bezemer PD, Dijkmans BA. Predictors of radiographic joint damage in patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:924-927. https://doi.org/10.1136/ard.60.10.924
  42. Jansen LM, van Schaardenburg D, van der Horst-Bruinsma I, van der Stadt RJ, de Koning MH, Dijkmans BA. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003;30:1691-1695.
  43. Hammer HB, Odegard S, Syversen SW, et al. Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69:150-154. https://doi.org/10.1136/ard.2008.103739
  44. Mease PJ. Improving the routine management of rheumatoid arthritis: the value of tight control. J Rheumatol 2010;37:1570-1578. https://doi.org/10.3899/jrheum.091064
  45. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission: Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007;66:1443-1449. https://doi.org/10.1136/ard.2007.071092
  46. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66 Suppl 3:iii56-iii60.
  47. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-637. https://doi.org/10.1136/ard.2009.123919
  48. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-48. https://doi.org/10.1002/art.1780380107
  49. Aletaha D, Smolen JS. The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007;21:663-675. https://doi.org/10.1016/j.berh.2007.02.004
  50. Uhlig T, Kvien TK, Pincus T. Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Ann Rheum Dis 2009;68:972-975. https://doi.org/10.1136/ard.2008.097345
  51. Thompson PW, Hart LE, Goldsmith CH, Spector TD, Bell MJ, Ramsden MF. Comparison of four articular indices for use in clinical trials in rheumatoid arthritis: patient, order and observer variation. J Rheumatol 1991;18:661-665.
  52. Pincus T. The American College of Rheumatology (ACR) core data set and derivative "patient only" indices to assess rheumatoid arthritis. Clin Exp Rheumatol 2005;23(5 Suppl 39):S109-S113.
  53. Centola M, Cavet G, Shen Y, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One 2013;8:e60635. https://doi.org/10.1371/journal.pone.0060635
  54. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010;303:1266-1273. https://doi.org/10.1001/jama.2010.375
  55. Wittkowski H, Kuemmerle-Deschner JB, Austermann J, et al. MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. Ann Rheum Dis 2011;70:2075-2081. https://doi.org/10.1136/ard.2011.152496

Cited by

  1. A proteomic profile of synoviocyte lesions microdissected from formalin-fixed paraffin-embedded synovial tissues of rheumatoid arthritis vol.12, pp.1, 2015, https://doi.org/10.1186/s12014-015-9091-8
  2. Isoquinoline alkaloids from Zanthoxylum simulans and their biological evaluation vol.68, pp.4, 2014, https://doi.org/10.1038/ja.2014.139
  3. Tumor-Associated and Disease-Associated Autoantibody Repertoires in Healthy Colostrum and Maternal and Newborn Cord Sera vol.194, pp.11, 2015, https://doi.org/10.4049/jimmunol.1402771
  4. Proteomics in rheumatology vol.18, pp.8, 2014, https://doi.org/10.1111/1756-185x.12821
  5. Calprotectin : a novel inflammatory marker in a sample of Egyptian children with β-thalassemia major vol.14, pp.2, 2014, https://doi.org/10.1097/01.mjx.0000472997.01107.c4
  6. How to manage rheumatoid arthritis according to classic biomarkers and polymorphisms? vol.12, pp.3, 2014, https://doi.org/10.1007/s11515-017-1452-4
  7. cDNA phage display for the discovery of theranostic autoantibodies in rheumatoid arthritis vol.65, pp.1, 2014, https://doi.org/10.1007/s12026-016-8839-1
  8. Increased Levels of S100A8/A9 in Patients with Peritonsillar Abscess: A New Promising Diagnostic Marker to Differentiate between Peritonsillar Abscess and Peritonsillitis vol.2017, pp.None, 2014, https://doi.org/10.1155/2017/9126560
  9. Synovial tissue research: a state-of-the-art review vol.13, pp.8, 2017, https://doi.org/10.1038/nrrheum.2017.115
  10. Calprotectin levels in rheumatoid arthritis and their correlation with disease activity: a meta-analysis vol.129, pp.5, 2014, https://doi.org/10.1080/00325481.2017.1319729
  11. Autoimmune arthritis induces paired immunoglobulin‐like receptor B expression on CD4+ T cells from SKG mice vol.47, pp.9, 2014, https://doi.org/10.1002/eji.201646747
  12. S100A8/A9 increases the mobilization of pro-inflammatory Ly6C high monocytes to the synovium during experimental osteoarthritis vol.19, pp.None, 2014, https://doi.org/10.1186/s13075-017-1426-6
  13. S100A8/A9 in Inflammation vol.9, pp.None, 2018, https://doi.org/10.3389/fimmu.2018.01298
  14. Fcγ receptor-mediated influx of S100A8/A9-producing neutrophils as inducer of bone erosion during antigen-induced arthritis vol.20, pp.None, 2018, https://doi.org/10.1186/s13075-018-1584-1
  15. S100A8 & S100A9: Alarmin mediated inflammation in tendinopathy vol.9, pp.None, 2014, https://doi.org/10.1038/s41598-018-37684-3
  16. Increased Plasma Levels of S100A8, S100A9, and S100A12 in Chronic Spontaneous Urticaria vol.64, pp.6, 2019, https://doi.org/10.4103/ijd.ijd_375_18
  17. miRNAs Regulate Cytokine Secretion Induced by Phosphorylated S100A8/A9 in Neutrophils vol.20, pp.22, 2019, https://doi.org/10.3390/ijms20225699
  18. Circulating S100A8/A9 is potentially a biomarker that could reflect the severity of experimental colitis in rats vol.6, pp.2, 2020, https://doi.org/10.1016/j.heliyon.2020.e03470
  19. Can Calprotectin Show Subclinical Inflammation in Familial Mediterranean Fever Patients? vol.35, pp.10, 2014, https://doi.org/10.3346/jkms.2020.35.e63
  20. Association of Serum Calprotectin Concentrations with Mortality in Critically Ill and Septic Patients vol.10, pp.11, 2014, https://doi.org/10.3390/diagnostics10110990
  21. A Cross-Sectional and Longitudinal Study to Define Alarmins and A-SAA Variants as Companion Markers in Early Rheumatoid Arthritis vol.12, pp.None, 2014, https://doi.org/10.3389/fimmu.2021.638814
  22. Impact of Exercise Intensity on Calprotectin Levels in Healthy Volunteers and Patients with Inflammatory Rheumatic Diseases vol.11, pp.5, 2014, https://doi.org/10.3390/life11050377
  23. The Role of Plasma Calprotectin in Non-infectious Uveitis vol.46, pp.8, 2014, https://doi.org/10.1080/02713683.2020.1867749
  24. DSS-induced inflammation in the colon drives a proinflammatory signature in the brain that is ameliorated by prophylactic treatment with the S100A9 inhibitor paquinimod vol.18, pp.1, 2014, https://doi.org/10.1186/s12974-021-02317-6